PillRx only · Injection, Powder, For Solution · Intravenous
Meropenem
Meropenem
8 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US21 NDCs
8 active makers
8 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 9 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$4.838
Latest avg · Jul 22, 2026
-14%
Since Dec 17, 2025
8
Active US suppliers
48%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
8.1K
Rx · 2026 Q1
104K
Units dispensed
-36%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it8 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Fresenius Kabi USA, LLC | unknown | 6 | SUPPLYING |
| WG Critical Care, LLC | unknown | 5 | SUPPLYING |
| Hospira, Inc. | unknown | 4 | SUPPLYING |
| Amneal Pharmaceuticals LLC | unknown | 2 | SUPPLYING |
| Xellia Pharmaceuticals USA LLC | unknown | 2 | SUPPLYING |
| Sagent Pharmaceuticals | unknown | 2 | SUPPLYING |
| Eugia US LLC | unknown | 2 | SUPPLYING |
| BluePoint Laboratories | unknown | 0 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.